Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry

Single Donor Human Plasma (Blood Derived) from Innovative Research was used in the following study:

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry

J.J.M Rood, M.J.van Haren, J.H.Beijnen, R.W.Sparidans

Journal of Pharmaceutical and Biomedical Analysis
January 2020

“…Osimertinib is a “third-generation’’ oral, irreversible, tyrosine kinase inhibitor. It is used in the treatment of non-small cellular lung carcinoma and spares wild-type EGFR. Due to its reactive nature, osimertinib is, in addition to oxidative routes, metabolized through GSH coupling and subsequent further metabolism of these conjugates. The extent of the non-oxidative metabolism of osimertinib is unknown, and methods to quantify this metabolic route have not been reported yet... For the evaluation of selectivity and matrix effect, human sodium-EDTA plasma of six individual donors were obtained from Innovative Research (Novi, MI, USA)…”

Related products available from Innovative Research also include:

• Single Donor Human Plasma (Blood Derived)
• Pooled Human Complement Plasma
• Pooled Human Plasma Apheresis Derived